DalCor Pharmaceuticals Stock

dalcorpharma.comHealthcare / BioTech & PharmaFounded: 2015

DalCor Pharmaceuticals, founded in 2015, is a biopharmaceutical company seeking to find better ways to treat cardiovascular disease through a combination of genetic exploration and clinical therapies. DalCor Pharmaceuticals’ proprietary development program, dalcetrapib, combines that approach to reduce the impact of myocardial infarction (MI) in patients. DalCor Pharmaceuticals is headquartered in Montreal, Canada.

Register for Details

For more details on financing and valuation for DalCor Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for DalCor Pharmaceuticals.

Register Today

DalCor Pharmaceuticals investors also invested in these private companies

CTI Life Sciences Fund
Sanderling Ventures
Investissement Quebec
Fonds de solidarité FTQ
Caisse de dépôt et placement du Québec
Fonds de Developpement Économique


Management Team

David Kallend MD
Chief Scientific Officer & Chief Medical Officer
Diane Sullivan
Chief Commercial Officer
Therese Heinonen
Co-Chief Development Officer & Vice President, Operations
Fouzia Laghrissi-Thode
Co-Chief Executive Officer
Robert Mcneil Ph.D
Founder & Co-Chief Executive Officer
Michael Dixon
Chief Financial Officer
Louise Proulx Ph.D
Co-Chief Development Officer

Board Members

Didier Leconte
Fonds de solidarité FTQ
Laurence Rulleau Ph.D
CTI Life Sciences Fund

Other companies like DalCor Pharmaceuticals in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

DalCor Pharmaceuticals secures $80m in Series D financing
DalCor Pharmaceuticals, a Montreal-based biopharmaceutical company with a focus on addressing cardiovascular disease, has secured $80 million in Series D financing. The round was backed by Fonds de Developpement Économique managed by Investissement Québec and Fonds Propres d’ Investissement Québec. Existing investors, such as Andes Growth, TB Pharma, Fonds de solidarité FTQ and CTI Life Sciences, also participated.
Updated on: Sep 24, 2023